Methoxyflurane
As of the edition of 20 October 2026, Methoxyflurane is a small molecule: marketed, first approved in 1962 (US); acts on GLRA1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Penthrane
- First approved
- 4 May 1962 (US)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- Knight Therapeutics; 3 holders in all
- Withdrawn from market
- 1 January 2001 (in some regions)
- Registered trials
- 27, 1 stopped early
- Disease areas
- Heart and blood vessels; Injuries; Nervous system; Urinary and reproductive; Cancer; Mouth and teeth
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GLRA1 | Glycine receptor subunit alpha-1 | P23415 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 1 | 1 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 11 | 8 | 2 | 0 |
| Phase 4 | 12 | 6 | 2 | 0 |
| All trials | 27 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Knight Therapeutics | Applicant | 2018 to now |